Live Breaking News & Updates on Cc Chemokine Receptor 4 Antagonist

Stay updated with breaking news from Cc chemokine receptor 4 antagonist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Rapt slapped with phase II hold on CCR4 prospect

On the verge of top-line data from its phase IIb trial with oral small-molecule CC chemokine receptor 4 (CCR4) antagonist zelnecirnon in atopic dermatitis (AD), due around the middle of this year, Rapt Therapeutics Inc. said the U.S. FDA has imposed a clinical hold on that study with the otherwise promising drug, also known as RPT-193, in AD as well as the phase IIa trial with the same compound in asthma. ....

Rapt Therapeutics Inc , Rapt Therapeutics , Rapt Therapeutics Inc , Rpt 193 , Atopic Dermatitis , Clinical Hold , Cc Chemokine Receptor 4 Antagonist , Liver Failure ,